First Quarter 2024 Earnings Presentation

April 30, 2024

Safe Harbor Statement and Other Matters

This presentation contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, guidance on Company and segment performance for the second quarter of 2024 and our expected commercialization of Opteon™ two-phase immersion cooling by 2026. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized, such as guidance relying on models based upon management assumptions regarding future events that are inherently uncertain. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties including the outcome or resolution of any pending or future environmental liabilities, the commencement, outcome or resolution of any regulatory inquiry, investigation or proceeding, the initiation, outcome or settlement of any litigation, remediation of material weaknesses and internal control over financial reporting, changes in environmental regulations in the U.S. or other jurisdictions that affect demand for or adoption of our products, anticipated future operating and financial performance for our segments individually and our company as a whole, business plans, prospects, targets, goals and commitments, capital investments and projects and target capital expenditures, plans for dividends or share repurchases, sufficiency or longevity of intellectual property protection, cost reductions or savings targets, plans to increase profitability and growth, our ability to develop and commercialize new products or technologies and obtain necessary regulatory approvals, our ability to make acquisitions, integrate acquired businesses or assets into our operations, and achieve anticipated synergies or cost savings, all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements also may involve risks and uncertainties that are beyond Chemours' control. Matters outside our control, including general economic conditions, geopolitical conditions and global health events, have affected or may affect our business and operations and may or may continue to hinder our ability to provide goods and services to customers, cause disruptions in our supply chains such as through strikes, labor disruptions or other events, adversely affect our business partners, significantly reduce the demand for our products, adversely affect the health and welfare of our personnel or cause other unpredictable events. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission, including in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 and in our Annual Report on Form 10-K for the year ended December 31, 2023. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.

We prepare our financial statements in accordance with Generally Accepted Accounting Principles (GAAP). Within this press release, we may make reference to Adjusted Net Income, Adjusted EPS, Adjusted EBITDA, Adjusted EBITDA Margin, Total Debt Principal, Net and Net Leverage Ratio which are non-GAAP financial measures. The Company includes these non-GAAP financial measures because management believes they are useful to investors in that they provide for greater transparency with respect to supplemental information used by management in its financial and operational decision making. Management uses Adjusted Net Income, Adjusted EPS, Adjusted EBITDA, and Adjusted EBITDA Margin, which adjust for (i) certain non-cash items, (ii) certain items we believe are not indicative of ongoing operating performance or (iii) certain nonrecurring, unusual or infrequent items to evaluate the Company's performance in order to have comparable financial results to analyze changes in our underlying business from period to period. Additionally, Total Debt Principal, Net and Net Leverage Ratio are utilized as liquidity measures to assess the cash generation of our businesses and on-going liquidity position.

Accordingly, the Company believes the presentation of these non-GAAP financial measures, when used in conjunction with GAAP financial measures, is a useful financial analysis tool that can assist investors in assessing the Company's operating performance and underlying prospects. This analysis should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. This analysis, as well as the other information in this press release, should be read in conjunction with the Company's financial statements and footnotes contained in the documents that the Company files with the U.S. Securities and Exchange Commission. The non-GAAP financial measures used by the Company in this press release may be different from the methods used by other companies. The Company does not provide a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures on a forward-looking basis because it is unable to predict with reasonable certainty the ultimate outcome of unusual gains and losses, potential future asset impairments and pending litigation without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For more information on the non-GAAP financial measures, please refer to the attached schedules or the table, "Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)" and materials posted to the Company's website at investors.chemours.com.

Chemours™

First Quarter 2024 Financial Summary

($ in millions unless otherwise noted; excludes per share amounts)

	1Q24	1Q23	Δ Yr/Yr
Net Sales	**$1,350**	**$1,536**	**$(186)**
Pre-Tax Income	$67	$173	$(106)
Pre-Tax Income Margin (%)	5%	11%	(6) pp
Net Income [1]	$52	$145	$(93)
Adj. Net Income [2]	$48	$148	$(100)
EPS [3]	**$0.34**	**$0.96**	**$(0.62)**
Adj. EPS [2,3]	**$0.32**	**$0.98**	**$(0.66)**
Adj. EBITDA [2,4]	**$193**	**$304**	**$(111)**
Adj. EBITDA Margin (%) [5]	**14%**	**20%**	**(6) pp**
Operating Cash Flow	**$(290)**	**$(124)**	**$(166)**
Capex	**$(102)**	**$(91)**	**$(11)**

[1] Net Income attributable to The Chemours Company

[2] Non-GAAP measures, including Adjusted Net Income, Adjusted EPS, and Adjusted EBITDA Margin, referred to throughout, principallyexclude the impact of recent litigation settlements for legacy environmental matters and associated fees, in addition to other unallocated items – please refer to the attached "GAAP Net Income (Loss) Attributable to Chemours to Adjusted Net Income, Adjusted EBITDA, and Adjusted EBITDA Margin Reconciliation (Unaudited)" table

[3] Calculation based on diluted share count

[4] Adjusted EBITDA excludes net income attributable to noncontrolling interests, net interest expense, depreciation and amortization, and all remaining provision for income taxes from Adjusted Net Income. Please refer to the attached "GAAP Net Income (Loss) Attributable to Chemours to Adjusted Net Income, Adjusted EBITDA, and Adjusted EBITDA Margin Reconciliation (Unaudited)" table

[5] Defined as Adjusted EBITDA divided by Net Sales

First Quarter vs Prior-Year Quarter

- **Net Sales:** Decreased by 12% to $1.4 billion, driven by decreased volumes in APM and TSS as well as lower pricing across the businesses
- **Earnings Per Share (EPS):**
  - GAAP EPS[3] of $0.34, down $(0.62) YoY
  - Adjusted EPS[3] of $0.32, down $(0.66) YoY
- **Adjusted EBITDA:** $193 million, down 37% YoY, primarily due to lower price and sales volumes, partially offset by cost-saving actions in TT
- **Adjusted EBITDA Margin:** Decreased to 14%, down from 20% in the prior-year quarter, primarily influenced by the factors outlined above
- **Operating Cash Flow:** $(290) million, driven by 2023 year-end net working capital timing actions unwind and lower net income
- **Capex:** $(102) million, up from $(91) million in the prior-year quarter

Chemours™

Adjusted EBITDA Bridge: 1Q24 versus 1Q23

($ in millions unless otherwise noted)



First Quarter vs Prior-Year Quarter

- **Price Declines:** Primarily driven by lower pricing in market-exposed customer portfolio within the TT segment, as well as lower pricing in legacy refrigerants in TSS and economically sensitive end-markets in APM
- **Volume Changes:** Primarily driven by continued weaker demand in economically sensitive end-markets within APM, as well as subdued demand in the Foam, Propellants and Other products portfolio and from automotive OEMs in TSS
- **Cost Reduction:** Primarily driven by improved cost profile resulting from cost-saving actions in TT

See reconciliation of Non-GAAP measures in the Appendix

[6] Total costs in the first quarter of 2024 include a $5 million unallocated item related to third-party costs associated with the TT Transformation Plan

Liquidity Position as of March 31, 2024

($ in millions unless otherwise noted)

Gross debt	$4.1B
Net Debt [9]	$3.3B
TTM Net Leverage [10]	3.7x

Q1'24 Cash Position:

- Unrestricted Cash: $0.7 billion
- Restricted Cash: $0.6 billion
- Total Cash: $1.4 billion



See reconciliations of Non-GAAP measures in the Appendix

Q1'24 Cash Flow Highlights:

- Operating Cash Flow: $(290) million
- Capex: $(102) million

Restricted Cash:

- Reflects $606 million as a part of the Water District Settlement Fund (per U.S. public water system settlement agreement)

Total Liquidity:

- Total Liquidity[8]: $1.6 billion
  - Unrestricted Cash: $0.7 billion
  - Revolving Credit Facility Capacity: $0.9 billion (net of outstanding letters of credit)

Q2'24 Outlook:

- Operating Cash Flow: $(500) million, attributable to the reduction of the $606 million of restricted cash held as part of the Water District Settlement Fund for which we will no longer maintain a reversionary interest upon final judgment
- Capex: $(80) million

[7] Total cash balances include $604 million and $607 million of restricted cash and restricted cash equivalents on Chemours' Balance Sheets as of December 31, 2023 and March 31, 2024, respectively, related principally to the Water District Settlement Fund.
[8] Total liquidity is calculated as the sum of $746 million unrestricted cash and cash equivalents and $853 million of revolving credit capacity, net of outstanding letters of credit. Restricted cash and restricted cash equivalents totaling $607 million is not included in this calculation
[9] Net Debt, which we also refer to herein as Total Debt Principal, Net, is calculated as gross debt less unrestricted cash and cash equivalents
[10] TTM Net Leverage reflects Total Debt Principal, Net at quarter-end divided by trailing twelve months of Adjusted EBITDA

Chemours™

Segment Performance

Titanium Technologies (TT) Business Summary

Q1 Highlights

- **Q1 Performance:** YoY Net Sales decreased due to declines in market-exposed customer portfolio, partially offset by index-based priced contractual stability. Volumes were flat as strength in APAC and EMEA regions was offset by weakness in North America and LatAm.
- Adjusted EBITDA was flat, primarily driven by cost reductions from the TT Transformation Plan, partially offset by price declines.
- **Sequential Performance:** Net Sales decrease was completely driven by decreases in volume. Adjusted EBITDA increase was driven by actions to allocate TiO_2 volumes to higher-yield regions, the timing of lower-cost ore consumption, and cost reductions from the TT Transformation Plan.

Q2 Outlook

- **2Q24 Outlook:** The Company expects sequential Net Sales growth of approximately 15%, reflecting the previously communicated improvement in the Company's TiO_2 orderbook. Adjusted EBITDA growth is expected to be generally in-line with the growth in Net Sales, with higher volumes and improved fixed cost absorption, partially offset by the timing of certain business overhead costs and the shift in timing of higher-cost ore consumption, much of which is anticipated for the second quarter.

- **Transformation Plan Update**: Eliminated approx. $90 million of operating expenses since plan announced. $50 million of this was in latter half of 2023. $40 million in YoY savings was achieved in Q1 2024 toward cost-out target of $125 million for FY24.

Q1 Net Sales

($ in millions)

	Total	Price	Volume	Currency
Yr/Yr %	(7)	(7)	0	0
Qtr/Qtr %	(10)	0	(10)	0



Q1 Adjusted EBITDA

($ in millions)

	Total
Yr/Yr %	0
Qtr/Qtr %	9



Margin[6]	23%	22%	11%	12%

Chemours™

[1-10] Refer to footnotes provided on the preceding slides

Thermal & Specialized Solutions (TSS) Business Summary

Q1 Highlights

- **Q1 Performance:** YoY Net Sales decrease driven by lower Auto OEM and FP&O* portfolio demand coupled with lower legacy HFC and contractual auto OEM pricing. These impacts were partially offset by increased demand for Opteon™ products in stationary end markets.
- Adjusted EBITDA decreased due to decreases in sales volume and price along with increased R&D investments in immersion cooling and next generation refrigerants.
- **Sequential Performance:** Net Sales increase primarily driven by seasonal refrigerant demand trends. This increase was partially offset by softer volumes in the FP&O product portfolio due to its exposure to construction markets, which remain weak.

Q2 Outlook

- **2Q24 Outlook:** The Company expects mid-teens sequential growth for both Net Sales and Adjusted EBITDA, driven by both seasonality and continued adoption of Opteon™ products. The projected sequential growth for Adjusted EBITDA incorporates a modest offset from higher input costs from non-Corpus Christi sourced materials to support the transition to Opteon™, lower fixed cost absorption on the Company's legacy refrigerant production, and ongoing investments in next generation refrigerants and immersion cooling. This increased investment, primarily in R&D, is anticipated to be approximately $15 million in 2024.

Q1 Net Sales

($ in millions)

	Total	Price	Volume	Currency
Yr/Yr %	(8)	(2)	(6)	0
Qtr/Qtr %	20	5	15	0



Q1 Adjusted EBITDA

($ in millions)

	Total
Yr/Yr %	(18)
Qtr/Qtr %	22



Margin[6]	30%	41%	38%	34%

*FP&O = Foam, Propellants and Other Products

[1-10] Refer to footnotes provided on the preceding slides

Chemours™

Thermal & Specialized Solutions – Business Summary

TSS Market Strength

Global leading provider of refrigerants, thermal management solutions, propellants, foam blowing agents, and specialty solvents

Category leader in next-gen low global warming potential ("GWP") refrigerant technology Opteon™

- Market-leading process technology at Corpus Christi, TX facility; 40% capacity expansion complete by YE 2024
- Project announced to increase capacity for low GWP foam blowing agents
- Commercialization of Opteon™ two-phase immersion cooling by 2026, pending appropriate regulatory approvals
- Robust international patent portfolio for products and methods, providing protection until the early to mid 2030s

Estimated mid-to-high single digit growth for TSS through the end of the decade with Adjusted EBITDA Margin averaging 30% or greater

TSS Key End Markets



Geography [11]



Product Type [11]



Adj. EBITDA margin of 37%[11]

[11] Data reflects Net Sales and Adjusted EBITDA for the trailing twelve months ended March 31, 2024

Two-Phased Data Center Immersion Cooling with Opteon™

Key Market Drivers

- Over 95% of data centers use traditional air- and water-cooled technologies
- Data centers are highly energy-intensive, with over 40% of energy dedicated to cooling IT equipment
- A mid-sized US data center consumes approximately 300,000 gallons of water per day
- Next-generation GPUs and CPUs are driving the industry to evaluate liquid cooling

Why Two-Phase Immersion Cooling?

- Little to no water usage
- Direct-to-chip and single-phase immersion cooling require additional air-cooled or secondary refrigerant loops and equipment
- Superior heat absorption performance: ~100x better than air, ~10x better than single-phase immersion cooling‡
- Up to a 90% reduction in energy consumption, which equates to a potential 40% reduction in total data center energy consumption
- Simplified maintenance compared to single-phase immersion cooling
- Lower total cost of ownership and greater flexibility compared to direct-to-chip and single-phase immersion cooling

The Technology



Key Advantages

Solution for future higher capacity computing energy and performance demands

- Low water usage
- Low GWP
- Low asset footprint
- Low energy usage
- Low maintenance

Source: Internal Estimates, ING THINK

‡*based on relative heat transfer coefficients*

Advanced Performance Materials (APM) Business Summary

Q1 Highlights

- **Q1 Performance:** YoY Net Sales decline driven by weaker demand in more economically sensitive and non-strategic end-markets and the tail impact of an extended, now-resolved maintenance outage at one of the Company's manufacturing sites. Prices decreased due to mix and softer market dynamics vs. the prior year.
- Adjusted EBITDA decline driven by the aforementioned decrease in price, lower volume driving lower fixed cost absorption, and the aforementioned outage for maintenance, partially offset by lower input costs.
- **Sequential Performance:** Net Sales decrease driven by continued soft demand in economically sensitive end markets in the Advanced Materials product portfolio and specific product lines within the Performance Solutions product portfolio.

Q1 Net Sales

($ in millions)

	Total	Price	Volume	Currency
Yr/Yr %	(23)	(5)	(18)	0
Qtr/Qtr %	(8)	(1)	(8)	1



Q2 Outlook

- **Q2 Outlook:** The Company expects APM Net Sales to experience growth in the low-teens, driven by growth in the Performance Solutions product portfolio. The Company also expects a slight improvement in the performance of the Advanced Materials product portfolio, reflecting a modest recovery in end markets. Adjusted EBITDA is expected to approach a 30% sequential increase in the APM business, as mix and fixed cost absorption improve with higher volumes.

Q1 Adjusted EBITDA

($ in millions)

	Total
Yr/Yr %	(64)
Qtr/Qtr %	(25)



Margin[6]	17%	23%	22%	10%

[1-10] Refer to footnotes provided on the preceding slides

Appendix

Segment Net Sales and Adjusted EBITDA (Unaudited)

($ in millions)	Three Months Ended March 31, 2024	Three Months Ended March 31, 2023	Three Months Ended December 31, 2023
SEGMENT NET SALES			
Titanium Technologies	$ 588	$ 632	$ 651
Thermal & Specialized Solutions	449	486	374
Advanced Performance Materials	299	388	325
Other Segment	14	30	11
Total Company	$ 1,350	$ 1,536	$ 1,361
SEGMENT ADJUSTED EBITDA			
Titanium Technologies	$ 70	$ 70	$ 64
Thermal & Specialized Solutions	$ 151	$ 185	$ 124
Advanced Performance Materials	$ 30	$ 84	$ 40
Other Segment	$ 2	$ 10	$ -
SEGMENT ADJUSTED EBITDA MARGIN			
Titanium Technologies	12%	11%	10%
Thermal & Specialized Solutions	34%	38%	33%
Advanced Performance Materials	10%	22%	12%
Other Segment	14%	33%	0%

Chemours™

GAAP Net Income (Loss) Attributable to Chemours to Adjusted Net Income, Adjusted EBITDA, and Adjusted EBITDA Margin Reconciliation (Unaudited)
GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio (Page 1/2)

($ in millions except per share amounts)	Three Months Ended March 31,				Three Months Ended December 31,		Twelve Months Ended March 31,	
	2024		2023		2023		2024	2023
	$ amounts	$ per share*	$ amounts	$ per share*	$ amounts	$ per share*	$ amounts	$ amounts
Total Company Net Sales	$ 1,350		$ 1,536		$ 1,361		$ 5,841	$ 6,566
Income (loss) before taxes	67		173		(71)		(424)	634
Income (loss) before taxes margin %	5%		11%		(5)%		(7)%	10%
Net income (loss) attributable to Chemours (1)	$ 52	$ 0.34	$ 145	$ 0.96	$ (18)	$ (0.12)	$ (330)	$ 489
Non-operating pension and other post-retirement employee benefit income	(1)	(0.01)	—	—	(1)	(0.01)	(1)	(4)
Exchange (gains) losses, net	(1)	(0.01)	7	0.05	17	0.11	30	23
Restructuring, asset-related, and other charges	4	0.03	16	0.11	11	0.07	141	15
Loss (gain) on extinguishment of debt	—	—	—	—	—	—	1	(7)
Gain on sales of assets and businesses, net	(3)	(0.02)	—	—	(4)	(0.03)	(113)	(21)
Transaction costs	—	—	—	—	9	0.06	16	—
Qualified spend recovery	(7)	(0.05)	(14)	(0.09)	(11)	(0.07)	(47)	(58)
Litigation-related charges	—	—	1	0.01	89	0.60	764	21
Environmental charges	—	—	—	—	—	—	9	198
Adjustments made to income taxes	2	0.01	(4)	(0.03)	(14)	(0.09)	(13)	30
Provision for (benefit from) income taxes relating to reconciling items	2	0.01	(3)	(0.02)	(32)	(0.21)	(131)	(40)
Adjusted Net Income	$ 48	$ 0.32	$ 148	$ 0.98	$ 46	$ 0.31	$ 326	$ 646
Net income attributable to non-controlling interests	—		—		—		1	—
Interest expense, net	63		42		63		229	164
Depreciation and amortization	71		79		74		299	297
All remaining provision for (benefit from) income taxes	11		35		(7)		49	155
Adjusted EBITDA	$ 193		$ 304		$ 176		$ 904	$ 1,262

Chemours™

GAAP Net Income (Loss) Attributable to Chemours to Adjusted Net Income, Adjusted EBITDA, and Adjusted EBITDA Margin Reconciliation (Unaudited)
GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio (Page 2/2)

($ in millions except per share amounts)	Three Months Ended March 31, 2024		Three Months Ended March 31, 2023		Three Months Ended December 31, 2023		Twelve Months Ended March 31, 2024	Twelve Months Ended March 31, 2023
	$ amounts	$ per share*	$ amounts	$ per share*	$ amounts	$ per share*	$ amounts	$ amounts
Adjusted EBITDA	$ 193		$ 304		$ 176		$ 904	$ 1,262
Total debt principal							$ 4,051	$ 3,673
Less: Cash and cash equivalents							(746)	(816)
Total debt principal, net							$ 3,305	$ 2,857
Net Leverage Ratio (calculated using GAAP earnings)							(7.8x)	4.5x
Net Leverage Ratio (calculated using Non-GAAP earnings)							3.7x	2.3x
Weighted-average number of common shares outstanding - basic	149,035,200		148,997,084		148,861,410			
Weighted-average number of common shares outstanding - diluted (1)	150,050,369		151,179,265		149,939,877			
Basic earnings (loss) per share of common stock (2)	$ 0.35		$ 0.97		$ (0.12)			
Diluted earnings (loss) per share of common stock (1) (2)	$ 0.34		$ 0.96		$ (0.12)			
Adjusted basic earnings per share of common stock (2)	$ 0.32		$ 0.99		$ 0.31			
Adjusted diluted earnings per share of common stock (1) (2)	$ 0.32		$ 0.98		$ 0.31			

(1) In periods where the Company incurs a net loss, the impact of potentially dilutive securities is excluded from the calculation of EPS under U.S. GAAP, as their inclusion would have an anti-dilutive effect. As such, with respect to the U.S. GAAP measure of diluted EPS, the impact of potentially dilutive securities is excluded from our calculation for the three months ended December 31, 2023. With respect to the non-GAAP measure of adjusted diluted EPS, the impact of potentially dilutive securities is included in our calculation for the three months ended December 31, 2023 as Adjusted Net Income was in a net income position.
(2) Figures may not recalculate exactly due to rounding. Basic and diluted earnings per share are calculated based on unrounded numbers.

* Note: $ per share columns may not sum due to rounding.

Chemours™

Chemours™

Thank you!